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CASE REPORT
Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma
Hameem I. Kawsar, Alma Habib, Azhar Saeed and Anwaar Saeed
Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
ABSTRACT
A 54-year-old Caucasian male with history of hypertension, hyperlipidemia, insulin-dependent
diabetes mellitus, and chronic skin rash of 4 years presented to the emergency department
with worsening rash and weight loss. Physical examination revealed diffuse erythematous
rash, skin ulceration, bullae with associated paresthesia in the lower extremities, trunk,
bilateral upper extremities, and palms and soles. A computed tomography (CT) scan with
contrast showed a large, heterogenously enhancing pancreatic mass measuring 9.4 × 3.8 cm
with surrounding low-attenuation soft tissue thickening. Blood tests showed hemoglobin A1C
of 10.0%. Glucagon level was elevated to 2,178 (normal < 80 pg/dl). Endoscopic ultrasound
(EUS)-guided fine needle aspiration (FNA) from the pancreatic mass was suggestive of
pancreatic endocrine tumor. The tumor cells were positive for synaptophysin, chromogranin,
CD56, and pan-cytokeratin with focal positivity for glucagon, suggestive of glucagonoma. The
patient underwent distal pancreatectomy along with splenectomy and cholecystectomy. The
glucagon level normalized to 25 pg/dl within a week of tumor resection, and during his
6-week outpatient follow up, skin rash had completely resolved.
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1. Introduction
Necrolytic migratory erythema (NME) is a rare cuta-
neous paraneoplastic manifestation of glucagonoma.
Glucagonoma is a tumor of alpha cells of pancreas
that secret glucagon, and plays a major role in blood
glucose hemostasis. Elevated glucagon level due to
glucagonoma can cause a variety of clinical manifes-
tations including weight loss, diabetes, and NME.
Misdiagnosis of paraneoplastic cutaneous manifesta-
tion could delay the diagnosis of glucagonoma. Here,
we present an interesting case of chronic skin rash
which was treated as eczema for more than 4 years,
and recently as urticarial vasculitis, which was actu-
ally NME of glucagonoma. The skin rash has resolved
completely with resection of the tumor.
2. Case description
A 54-year-old Caucasian male with past medical history
of hypertension, hyperlipidemia, insulin-dependent dia-
betes mellitus, and chronic skin rash presented to the
emergency department (ED) with skin rash of 4-year
duration that had worsened over the preceding 2
weeks. He was diagnosed with eczematous skin disease
about 4 years ago and treated with topical steroid inter-
mittently with variable response. About 2months ago, he
was started on doxycycline and oral prednisone for
unremitting skin lesions. However, he had poor glycemic
control with use of prednisone, and hemoglobin A1c
(HbA1c) increased from 6.0% to 10.0%. A skin biopsy
was done for a definitive diagnosis of this chronic skin
lesion, and it was reported as urticarial vasculitis.
Prednisone was discontinued for poor glycemic control,
and dapsone was added. During the following 2 weeks,
the rash progressed to involve both lower extremities,
upper extremities, and trunk with swelling and bullae
with no other identifiable trigger. In the ED, he reported
of unintentional weight loss of 30 lbs in the preceding 3
months and denied any family history of malignancy or
autoimmune disease. He also denied history of smoking,
anorexia, or abdominal pain. On examination, the
affected area of the skin was warm with diffuse erythema
and edema throughout both lower extremities.
Ulceration was prominent in the right lower extremity,
trunk, bilateral upper extremities, and palms and soles
(Figure 1). There were bullae with associated paresthesia.
The patient was unable to bear weight and experienced
sharp shooting pain in his bilateral feet. Further work up
was directed to rule out other etiologies of skin rash and
weight loss, including nutritional deficiency, infection,
autoimmune disease, and occult malignancy. He had
elevated erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) at 32 (reference range
0–20 mm/h) and 8.05 (reference range <1.0 mg/dl),
respectively. Comprehensive work up for autoimmune
disease and infectious etiology were negative. Because of
his recent significant weight loss, a computed tomogra-
phy (CT) scan of chest, abdomen, and pelvis with con-
trast was done to rule out occult malignancy, which
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showed a large, heterogenously enhancing mid to distal
pancreatic mass measuring 9.4 × 3.8 cm with surround-
ing low-attenuation soft tissue thickening (Figure 2).
Tumor marker, CA 19–9 was 2.0 (reference range < 35
U/ml); however, glucagon was elevated to 2,178 (normal
< 80 pg/dl). Prolactin, T4, and TSH levels were within
normal range. Hemoglobin and hematocrit were low at
12.2 (reference range 13.5–16.5 gm/dl) and 36.1 (refer-
ence range 40–50%), respectively. Liver enzymes were
within normal limit. There was no leukocytosis or fever,
indicating cellulitis less likely.
An endoscopic ultrasound (EUS) was done which
showed an isoechoic mass (6.5 cm × 3.8 cm) in the
body/tail area of the pancreas, and fine needle aspira-
tion (FNA) samples were obtained from the mass.
Immunohistochemical stains were positive for synap-
tophysin, chromogranin, CD56, pancytokeratin, and
focal positivity for glucagon suggestive of glucago-
noma. He underwent distal pancreatectomy with
splenectomy and cholecystectomy. Tissue specimens
showed a pancreatic well-differentiated neuroendo-
crine tumor, WHO grade 1. The tumor cells were
positive for chromogranin and synaptophysin and
negative for nuclear beta-catenin. Resected margins
were free of malignant involvement. None of the 26
lymph nodes collected during surgery were positive.
The punch biopsy of the skin lesion showed psoriasi-
form inflammatory reaction and confluent parakera-
tosis (Figure 3). The glucagon level normalized to 25
pg/ml (from 2,718 pg/ml) 5 days after the surgical
Figure 1. Affected area of the skin showed desquamation, erythema, and ulceration in lower extremities and sole.
Figure 2. A CT scan with contrast of abdomen showed
a large, heterogenously enhancing mid to distal pancreatic
mass measuring 9.4 × 3.8 cm with surrounding low-
attenuation soft tissue thickening (white arrows).
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resection of tumor. Dapsone and doxycycline were
discontinued and the patient was discharged home.
During 6-week outpatient follow up, he had complete
resolution of the skin lesions.
3. Discussion
In 1942, Dr. Becker and his colleagues described a 45-
year-old female who was hospitalized with a history of
widespread pruritic erythematovesicular skin eruptions
for 8 months that was unresponsive to roentgen irradia-
tion, ultraviolet irradiation, systemic iodides, ferrous sul-
fate, and high vitamin diet. She died of circulatory
collapse and respiratory failure due to ‘shock phenom-
enon’. Postmortem examination revealed a pancreatic
tumor replacing the tail and body of the pancreas. This
is the first known reported case of association of pan-
creatic cancer with cutaneous manifestations [1]. This
characteristic skin lesion is now known as necrolytic
migratory erythema (NME) due to its migratory nature,
erythematous appearance, and histological findings of
necrosis of the upper spinous layer [2]. However, this
finding in biopsy is nonspecific and can be absent or
focally present on biopsy [3]. In 1966, Dr.McGavran and
his colleagues described the first case of glucagonoma in
a 42-year-old female who presented with bullous and
eczematoid dermatitis of the hands, feet, and legs [4].
The diagnosis of glucagonoma is made based on
increased serum glucagon level and presence of glucagon
secreting tumor in the pancreas. Glucagonoma present-
ing with constellation of symptoms, known as glucago-
noma syndrome, was described in 1974 based on the
findings in nine patients presenting with NME, stomati-
tis, weight loss, and diabetes in seven patients [5]; how-
ever, this syndrome was extensively reviewed in 1978 by
Dr. Swenson and his colleagues [6]. While NME is
described as a characteristic cutaneous manifestation of
glucagonoma, it has been reported in other diseases, such
as other malignancies (e.g., hepatocellular carcinoma,
bronchial carcinoma, jejunal adenocarcinoma, etc.),
celiac disease, chronic pancreatitis, liver cirrhosis, inflam-
matory bowel disease, and nutritional deficiencies [7].
NME is a cutaneous paraneoplastic manifestation of
glucagonoma, and can be the only presenting feature
in approximately 70% of patients [8]. This rash is
commonly pruritic, painful, erythematous, and well-
demarcated plaques [9,10], and may involve the face,
trunk, extremities, and perineum [11]. The biopsy of
the skin lesion may show superficial epithelial necrosis
of the spinous layer of epidermis and vacuolated ker-
atinocytes; however, overlapping dermatoses such as
pemphigoid, psoriasis, or eczema can sometime make
the diagnosis challenging [2]. High serum glucagon
level due to glucagonoma has glucagon-like peptide
(GLP-1) activity that causes a shift in catabolic state
and caloric consumption resulting in weight loss.
Direct or indirect effect of catabolic state induced by
glucagon with resultant deficiency of fatty acids, amino
acids, and minerals essential for epidermal growth and
turnover results in the development of the character-
istic findings of NME [12–15]. Intermittent amino
acids and fatty acid infusion via peripheral vascular
access has been reported to be successfully used to
treat NME in the glucagonoma syndrome. However,
other symptoms related to glucagonoma syndrome
does not improve by this infusion [16]. Treatment of
glucagonoma with octreotide or surgical resection of
tumor results in resolution of NME.
There are published reports of characteristic skin
lesions that aid in diagnosis of underlying glucago-
noma [17–19]; however, there are also reports of
delayed diagnosis of glucagonoma due to misdiagno-
sis or delayed diagnosis of skin lesions (Table 1).
Oftentimes, the patients with glucagonoma presents
with skin lesions that is diagnosed as dermatitis,
psoriasis, or eczema and treated with topical and/or
oral steroid with variable responses. Our patient had
diabetes and skin rash for more than 4 years. His
diabetes was treated with insulin, and skin rash was
diagnosed as eczema by his dermatologist, and trea-
ted with topical steroid with variable response. Due to
the chronicity of the rash, and not resolving in 4
years, he was treated with doxycycline and oral ster-
oid, which caused poor glycemic control requiring
discontinuation of steroid therapy. Dapsone was
added by his physician due to skin biopsy findings
of urticarial vasculitis; however, his rash worsened
with significant weight loss requiring ED visit. His
skin rash completely resolved within 6 weeks of sur-
gical resection of the glucagonoma. This case illus-
trates a delayed diagnosis of glucagonoma for
approximately 4 years due to misdiagnosis of his
skin lesion, and not initiating further investigation
of the underlying etiology in a timely manner.
In conclusion, unremitting skin lesions associated
with diabetes/hyperglycemia and/or weight loss needs
further investigations to rule out other etiologies
Figure 3. A biopsy of skin lesion showing psoriasiform
inflammatory reaction and confluent parakeratosis.
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including nutritional deficiencies, specially zinc, vita-
mins, and iron; infectious etiology and occult malig-
nancies. If glucagon level is elevated, an abdominal
imaging is needed to localize the source of glucagon-
secreting tumor. A high degree of clinical suspicion is
necessary for early diagnosis of glucagonoma because
of the rarity of the disease as well as association with
nonspecific skin lesions.
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